Trial · NCT05762640
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Survival until HSCT | Day 0 until HSCT, up to 8 weeks | |
| Secondary | Rate of patients achieving a complete response | Day 7, Day 14, Day 21, Day 28, Week 8, and Day-1 of the conditioning for HSCT | To evaluate the efficacy of Ruxolitinib |
| Secondary | Rate of patients achieving a partial response | Day 7, Day 14, Day 21, Day 28, Week 8, and Day-1 of the conditioning for HSCT | To evaluate the efficacy of Ruxolitinib |
| Secondary | Delay to obtain complete response | Day 0 up to Day-1 of the conditioning for HSCT | To evaluate the efficacy of Ruxolitinib |
| Secondary | Delay to obtain partial response | Day 0 up to Day-1 of the conditioning for HSCT | To evaluate the efficacy of Ruxolitinib |
| Secondary | Incidence of HLH reactivation | Day 0 up to Day-1 of the conditioning for HSCT | HLH reactivation after achieving complete or partial response. |
| Secondary | Timing of HLH reactivation | Day 0 up to Day-1 of the conditioning for HSCT | HLH reactivation after achieving complete or partial response. |
| Secondary | Occurrence of a viral infection de novo or worsening of pre-existing viral infection(s) | During Ruxolitinib treatment | To evaluate treatment tolerance |
| Secondary | Occurrence of adverse effects reported in the product information for Ruxolitinib | During Ruxolitinib treatment | To evaluate treatment tolerance |
| Secondary | Concentration of Ruxolitinib in blood | Blood sampling: Day 0, weekly until week 8 of treatment and at Day-8 prior to the conditioning for HSCT | to evaluate Pharmacokinetics |
| Secondary | Concentration of Ruxolitinib in cerebrospinal fluid | Blood sampling: Day 0, weekly until week 8 of treatment and at Day-8 prior to the conditioning for HSCT | to evaluate Pharmacokinetics |
| Secondary | Cytokine profile and gene expression | Day 0, Weekly until week 8 of treatment | Assess through measurement of IFNγ, TNFα, Interleukin (IL)-6, IL-2, IL-10, IL-18, IL-1b, and CXCL9 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05762640/registered